<code id='C10CC6BC84'></code><style id='C10CC6BC84'></style>
    • <acronym id='C10CC6BC84'></acronym>
      <center id='C10CC6BC84'><center id='C10CC6BC84'><tfoot id='C10CC6BC84'></tfoot></center><abbr id='C10CC6BC84'><dir id='C10CC6BC84'><tfoot id='C10CC6BC84'></tfoot><noframes id='C10CC6BC84'>

    • <optgroup id='C10CC6BC84'><strike id='C10CC6BC84'><sup id='C10CC6BC84'></sup></strike><code id='C10CC6BC84'></code></optgroup>
        1. <b id='C10CC6BC84'><label id='C10CC6BC84'><select id='C10CC6BC84'><dt id='C10CC6BC84'><span id='C10CC6BC84'></span></dt></select></label></b><u id='C10CC6BC84'></u>
          <i id='C10CC6BC84'><strike id='C10CC6BC84'><tt id='C10CC6BC84'><pre id='C10CC6BC84'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:52496
          People waiting in line, standing in between red rope. -- first opinion coverage from STAT
          Adobe

          Health care providers and health insurance companies are closing the books on their third quarters, and one major question continues to hang over them: How much care is everyone actually getting, now that Covid-19 isn’t scaring so many away from doctors and hospitals?

          The short answer, according to financial analysts and the companies themselves: It appears people continue to fill prescriptions, see their doctors, and get recommended surgeries.

          advertisement

          For health insurers, those trends mean they will have to deposit more money into the bank accounts of providers — perhaps more than they predicted.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          FDA seeks to regulate lab

          AdobeTheFoodandDrugAdministrationonFridayannounceditsintentiontostartregulatingtestsdevelopedinlabor